Clinical Trials

Breast Neoplasms

NCT04059484 2026-02-24

AMEERA-3

367 enrolled 30 charts

Phase 2 Active not recruiting

Breast Cancer Metastatic

NCT06105632 2026-02-13

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

333 enrolled

Breast Neoplasms, Recurrence

NCT02007512 2025-09-02

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

247 enrolled 27 charts

Phase 2 Active not recruiting

Breast Neoplasms

NCT06957379 2025-05-04

Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy

78 enrolled

Breast Neoplasms

NCT03659136 2025-02-24

The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

103 enrolled 16 charts

Breast Neoplasms

NCT03272477 2024-04-17

TP-II

257 enrolled

Breast Neoplasms

NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

NCT03312738 2024-01-23

BOLERO-5

159 enrolled 25 charts

Breast Neoplasms

NCT02258451 2023-11-24

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

283 enrolled 22 charts

Breast Neoplasms

NCT01698918 2023-05-03

BOLERO-4

202 enrolled 19 charts

Breast Neoplasms

NCT05079360 2023-03-24

Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT02894398 2023-03-13

INGE-B

388 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT02049957 2023-02-08

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

118 enrolled 30 charts

Breast Neoplasms

NCT03291886 2022-06-21

Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

133 enrolled

Breast Neoplasms

NCT00676663 2022-05-11

ENCORE301

130 enrolled 18 charts

Breast Neoplasms, Mammary Neoplasms, Animal

NCT01783444 2021-02-26

BOLERO-6

309 enrolled 19 charts

Breast Neoplasms, Neoplasm Metastasis

NCT01381874 2019-04-11

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

297 enrolled 19 charts

Breast Neoplasms, Neoplasm Metastasis

NCT01605396 2019-03-25

MK-8669-064

80 enrolled 13 charts

Breast Neoplasms

NCT00728949 2018-06-06

A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

93 enrolled 14 charts

Breast Neoplasms

NCT00615524 2018-01-12

Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms, Neoplasm Metastasis

NCT01234857 2017-05-31

A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)

115 enrolled

Breast Neoplasms

NCT02069093 2017-02-13

Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer

92 enrolled 9 charts

Advanced Breast Cancer

NCT01151046 2016-05-12

Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

118 enrolled 13 charts

Breast Neoplasms

NCT00372996 2015-10-28

Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

219 enrolled 11 charts

Breast Neoplasms

NCT01004081 2015-10-02

Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding

54 enrolled

Breast Neoplasms

NCT00767520 2013-02-28

Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer

155 enrolled 19 charts

Breast Neoplasms

NCT00793546 2012-11-05

Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer

42 enrolled 7 charts

Breast Neoplasms

NCT01658176 2012-10-29

Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT00040014 2012-02-16

Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women

100 enrolled

Breast Neoplasms

NCT00174343 2011-04-22

Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients

46 enrolled

Breast Neoplasms

NCT00038103 2010-02-25

Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen

111 enrolled 14 charts